Levocarnitine

Carnitine Analog — ALIMENTARY TRACT AND METABOLISM

Key facts

Levocarnitine is an ofp drug in the Carnitine Analog class catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 3 molecular targets, including Cpt1b, Cpt2 and CPT1A. Recorded indications include Carnitine deficiency.

• Approval status: ofp (first approved 1985 by the FDA).
• Drug class: Carnitine Analog.
• Molecular targets: Cpt1b, Cpt2 and CPT1A (3 listed in DrugCentral).
• Indications: Carnitine deficiency.
• ATC code: A16AA01 (Amino acids and derivatives).
• Molecular formula: C7H15NO3; molecular weight 161.20 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Carnitine deficiency

Off-label uses (1)

• Recovery during viral myocarditis

Contraindications (7)

• Blood coagulation disorder
• Disease of liver
• Kidney disease
• Low blood pressure
• Obstruction of bile duct
• Seizure disorder
• Vitamin K Deficiency Induced Hypoprothrombinemia

Mechanism & targets

• Established pharmacologic class: Carnitine Analog

Molecular targets (3)

Target	Gene	Action	Activity
Carnitine O-palmitoyltransferase 1, muscle isoform	Cpt1b	unknown	Ki 4.00
Carnitine palmitoyltransferase 2	Cpt2	unknown	Ki 4.00
Carnitine O-palmitoyltransferase 1, liver isoform	CPT1A	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-12-27	FDA	—	SIGMA TAU	Yes

ATC classification

ATC code	Therapeutic hierarchy
A16AA01	ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Amino acids and derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Seizure	329.4
Parenteral nutrition associated liver disease	188.8
Hyperammonaemia	155.8
Status epilepticus	112.2
Fanconi syndrome	79.9
Ammonia increased	73.1
Epilepsy	68.6
Upper respiratory tract inflammation	58.8
Hypophosphataemic osteomalacia	45.2
Metabolic acidosis	43.6
Somnolence	42.9
Seizure cluster	41.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Levocarnitine is on its molecule page.

• Molecular formula: C₇H₁₅NO₃
• Molecular weight: 161.20 g/mol
• CAS number: —
• InChIKey: PHIQHXFUZVPYII-ZCFIWIBFSA-N
• PubChem CID: 10917

C[N+](C)(C)C[C@H](O)CC([O-])=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Levocarnitine used for?

DrugCentral lists the following indications for Levocarnitine: Carnitine deficiency.

How does Levocarnitine work?

Its molecular targets in DrugCentral include Cpt1b, Cpt2 and CPT1A.

When was Levocarnitine first approved?

Levocarnitine was first approved by the FDA in 1985.

What drug class does Levocarnitine belong to?

Levocarnitine is in the Carnitine Analog class.

What is the chemical formula of Levocarnitine?

Levocarnitine has the molecular formula C7H15NO3 and a molecular weight of 161.20 g/mol.

Sources

• DrugCentral drug card 513 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1149 — compound record and bioactivity
• PubChem CID 10917 — chemical identifiers
• DrugBank DB00583 — drug record
• FDA UNII 0G389FZZ9M — substance identity
• DailyMed: FDA labels for Levocarnitine — current prescribing information (label search)
• UniProt P50416 (CPT1A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.